the extremely on results call. to medicine we're be on making building afternoon, It company. precision thank report a pleasure today on our conference to progress on quarter an and joining quarter, to Good for it's and us Monique. you, you update you business everyone, and Thank has a provide our been another here third you
market year. who and services Breaking numbers. year. the saw the performance and our biopharma the researchers bit, little X potential it using million grew the we mechanism high-level our which market, $XX.X XXX% this down quarter share better very products expansion We disease, molecular first, by first product-related So product months which business, and Total during drugs mechanisms of over million and to strength for last of really a some action is profiling treatment. revenues strong are were subtypes academic quarter $X.X third driven of of and of see RNA continued differential for development into understand from
growth most well. in our as remains Biopharma important the but also seeing academic we're market market,
market European several and that now contributing filled strengthening Our is we open territories. sales
our RUO across fourth profiling of had However, early expected quarter recently have into from key XXXX. couple execution business, projects slip a we
highly on the in workflows, traditional Our HTG substantial We're and simplified a our business demonstrating into EdgeSeq are segment. We bioinformatics. projected sparing, billion profiling we technology, enable profiling business multiplexes differentiated is market, RNA sample into EdgeSeq can improves the which at digits. that very double believe these leveraging to build grow advantages is which $X.X based is thousands a
of diagnostic business impact Qiagen, of as XXXX, X lack a the active previously activity which quiet, of the number activity partnership This we lower decrease year. services Our partner, line indicated. precision to a been in by collaboration X development from felt development XXXX in went of this reflecting very and programs programs, in has our
profiling XX in HTG/Qiagen the the delivered the business. in signing about which partnership. first had with partnership strong tremendous the had PDP the customers programs results excited with of very a Qiagen, have These hope cultivated HTG with solution. biopharma combined X in months were new We of early our We're that
we We lost had a and in commercial be market momentum their partnership, to organization saw revenues. weakness PCR this of deliver pivoted to to and sequence in failed XXXX in the solutions. potential Qiagen the However, PDP support much
our we a year. adjusted guidance As this earlier result,
sequencing shift, rapid results noted their we including other to discontinue formally with reflected to platform, factors collaboration. Qiagen's than a this assumed. combined With expect decision and earlier, recent the from be now premature their previously I announcements, clinical weaker our shift mutual away
We are annual million revising $XX to XXXX. $XX year million now to for guidance full
As Gene but direct expected of future of needs agreements we collaborations a agreement. of Illumina will our as directly can contract and now to middleman communications and clear Thermo. streamlined HTG we with customers, more to with Qiagen's current the Qiagen returns it intend contract result biopharma Reader, notified have collaborations breach act by we're contract performance We to terminating that see and driver Qiagen to is agile a of continue, the lack what seat. we we new quickly Current with and the all of and control so eliminates be leverage development and the meet be will preexisting more Having our discontinuing believe
economics retain Qiagen commercial because likely which and direct organization enjoy to now partner. us significant through growth revenue focus working our make at relationship and In to better a diagnostics commercial is We but to biopharma recognize companion HTG. business strategies collaborations revenues good to of of collaborations. a X growth one channel forward return developing expect XXXX, split full a HTG's the in for margin obviously these development as a versus past, believe going with distribution the Qiagen. we We hope of the customer our HTG will also because more margins We will by this remains regaining control leveraging headway pharma with
number our strength a quarter. team, HTG important, continued our This at of agreements biopharma of signing advantages continues last of the programs number our We've XX grow. our increased the commercialization of agreement, XX the to subject, business growing from up sales biopharma in of slower active programs pipeline the And and as to under over that awareness customers. market on On of solution. we've the is efforts in collaboration pace of QX, to result new Qiagen in expand the targeted just end spite
pipeline of XXXX. client rest XXXX expect clients the of grow, to into to We this both the number programs of throughout and the number continue in and per
We also help last the biopharma Panel to anticipate and launch to the Autoimmune opportunities grow the partnerships. of of expect further business for new month our strengthen panels new introduction
many biopharma very Our with programs RUO CDx synergistic of helping profiling opportunities. the biopharma model and our future collaboration is to for feed pipeline
Our profiling optimistic in and the in gear, opportunity coming we're business our remains high about growth quarters.
to to diagnostic efforts, reasons. have proprietary a Center. hosted breast full our cancer in breast cancer of Pittsburgh our to development on Brodsky University HTG's chosen Adam multitude the KOL we breast conducted day Medical We're from first-ever We've program. Moving of pleased where in specifically doctor start strategically
we need. cancer of First, significant is believe area breast an unmet medical
among molecular solid premium. a there tumors. of it's already Next, finally, that's at treatments where availability biomarkers multiple embraced And is highest are incidence market tissue for a has the number and are and patients all required testing
dynamics guide these mind, intervention and market for cancer needs development. our And has diagnostic clinical prioritize breast clinical X HTG points With identified diagnostic specific broad points. to in we intervention
This conducted as research with L.E.K. by done by extensive market prioritization KOLs well was informed HTG. by by cancer research Consulting breast primary as
be breast as that full will product breast first panel. clinical-grade, intended build The part a initiative of our to transcriptome is we
our plex, many breast usage believe transcriptome. as to because include NGS-based very and as this and uniquely high suited We is the extremely our HTG XX,XXX cancer to low of do this expect sample genes, sensitivity. high We including entire our
development and this bioinformatics. product profiling weeks with with be transcriptome a laboratory where of it in would a a product a X X laboratory, other panel, standard. specialized that of standard today to available X initial needs highly RNA our business using or can test what a about investment HTG to cut any then bioinformatics, with labs, make expect We whole also This in it we days as replacing as to test our as well be cuts researchers the for developers just all follow more, RUO to for uses Clio RNA tissue Imagine, significant analysis. foundation clinical as run tissue, workforce, in that and plan in new XX to positioned and use all from taking built clinical single simplified takes or more including
capabilities RUO drive Last, plan new to continue market bring continue we business. assays our and to the to profiling to to
first market our content, launched is all will even market RUO for transcriptome Panel profiling we and This MS, new profiling. that a RNA lupus RUO product, larger HTG's believe than RA, we gene opportunity believe that autoimmune our that program the we month, breast high Autoimmune come will mentioned, be conditions. molecular targets also up business. that just other entire As from an for further The and product this opens drive oncology, revenue autoimmune
our control, profiling own we feel that namely In areas business starting RUO to diagnostics. and build performing directly our have summary, we well been in we preparatory the can
market RUO we opportunity and profiling year-over-year shown significant. business has growth, the for is quarter-over-quarter HTG and Our consistent believe
the customers product and programs continue We our expect now first to and our proprietary HTG are number biopharma have to number product. of expand clinical rapid that we making the In to roadmap develop diagnostics, our technology. progress leverage of
customers our have control in for and and engage in clear in collaborations in new new momentum collaborations. Qiagen, retaking in path and previously see where bringing and regain both coming programs with we are the Lastly, through customers to look working been a months. forward We contract HTG we directly business will
over our turn to financials. that, review call With I'd like the to Shaun to QX
